Interstrand Crosslink Repair as a Target for HDAC Inhibition

Trends Pharmacol Sci. 2017 Sep;38(9):822-836. doi: 10.1016/j.tips.2017.05.009. Epub 2017 Jul 4.

Abstract

DNA interstrand crosslinks (ICLs) covalently connect complementary DNA strands. Consequently, DNA replication and transcription are hampered, DNA damage responses (DDR) are initiated, and cell death is triggered. Therefore, drugs inducing ICLs are effective against rapidly growing cancer cells. However, tumors engage a complicated enzymatic machinery to repair and survive ICLs. Several factors, including the post-translational acetylation/deacetylation of lysine residues within proteins, control this network. Histone deacetylases (HDACs) modulate the expression and functions of DNA repair proteins which remove ICLs and control the accessibility of chromatin. Accordingly, histone deacetylase inhibitors (HDACi) are small, pharmacologically and clinically relevant molecules that sensitize cancer cells to ICL inducers. We discuss the mechanism of ICL repair and targets of HDACi within this pathway.

Keywords: DNA double-strand breaks; HDAC; chloroethylnitrosoureas; homologous recombination; interstrand crosslink repair; platinum compounds.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA Breaks, Double-Stranded
  • DNA Damage
  • DNA Repair*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylases / metabolism
  • Humans
  • Intercalating Agents / pharmacology

Substances

  • Histone Deacetylase Inhibitors
  • Intercalating Agents
  • Histone Deacetylases